14.1 Non-Sterile Compounding (USP <795>) & Liquid Formulations

14.1 Non-Sterile Compounding (USP <795>) & Liquid Formulations

Pediatric pharmacotherapy is constrained by a profound shortage of commercially available, age-appropriate liquid formulations. More than 40% of medications administered to hospitalized pediatric and neonatal patients must be compounded or manipulated extemporaneously to achieve weight-based dosing (mg/kg or mg/m²). When preparing non-sterile pediatric liquids, clinical pharmacists must apply the revised United States Pharmacopeia (USP) Chapter <795> standards, select chemically compatible suspending vehicles, critically appraise stability-indicating analytical literature, and identify non-crushable solid dosage forms to prevent fatal formulation errors.

---

USP <795> Regulatory Framework & Default Beyond-Use Dating (BUD)

Under revised USP <795> (effective November 1, 2023), default Beyond-Use Dates (BUD) for non-sterile compounded preparations (CNSPs) packaged in tight, light-resistant containers are established based on water activity ($a_w$), presence of antimicrobial preservatives, route of administration, and storage temperature, in the absence of published stability-indicating data or specific USP-NF monographs.

USP <795> Water Activity Classification & Default Oral Liquid BUDs:

┌──────────────────────────────────────┬─────────────┬──────────────────────┬──────────────┐
│ Formulation Type                     │ Water Act.  │ Storage Temperature  │ Maximum BUD  │
├──────────────────────────────────────┼─────────────┼──────────────────────┼──────────────┤
│ Non-Preserved Aqueous Oral Liquid    │ aw ≥ 0.60   │ Refrigerated (2°–8°C)│ 14 Days      │
│ Preserved Aqueous Oral Liquid        │ aw ≥ 0.60   │ Room Temp or 2°–8°C  │ 35 Days      │
│ Non-Aqueous Oral Formulation         │ aw < 0.60   │ Room Temp or 2°–8°C  │ 90 Days      │
│ Non-Aqueous Topical / Mucosal Form   │ aw < 0.60   │ Room Temp or 2°–8°C  │ 180 Days     │
└──────────────────────────────────────┴─────────────┴──────────────────────┴──────────────┘

Water Activity ($a_w$) and Critical Constraints

1. Aqueous Formulations ($a_w \ge 0.60$): Water activity measures the unbound, free water available for microbial proliferation and hydrolytic degradation. Oral suspensions, solutions, and emulsions prepared with water, syrups, or aqueous commercial vehicles fall into this category.
   • Non-Preserved Aqueous Oral Liquids: Maximum BUD is 14 days under refrigeration (2°C to 8°C). Storing non-preserved aqueous liquids at room temperature is non-compliant due to rapid bacterial and fungal proliferation.
   • Preserved Aqueous Oral Liquids: Formulations containing validated antimicrobial preservatives (e.g., potassium sorbate, sodium benzoate, methylparaben, propylparaben) have a maximum BUD of 35 days at either Controlled Room Temperature (CRT, 20°C to 25°C) or under refrigeration (2°C to 8°C).
2. Non-Aqueous Formulations ($a_w < 0.60$): Systems formulated with non-aqueous vehicles (e.g., fixed vegetable oils, medium-chain triglycerides, polyethylene glycol [PEG], mineral oil, or dry powders in gelatin/HPMC capsules). Oral non-aqueous forms carry a default BUD of up to 90 days at CRT or refrigerated; non-aqueous topical or mucosal forms carry up to 180 days.
3. Starting Component Expiration Limits: The assigned BUD must never exceed the shortest remaining expiration date of any starting component, active pharmaceutical ingredient (API), or commercial product used in compounding. If commercial tablets expiring in 20 days are crushed into a preserved vehicle, the maximum permissible BUD is 20 days, not 35 days.

---

Commercial Pediatric Suspending Vehicles & Compounding Chemistry

When converting insoluble solid dosage forms into homogeneous oral liquids, selecting the correct suspending vehicle is critical to prevent irreversible sedimentation, maintain physical redispersibility, and buffer the active drug at its optimum stability pH.

Flocculation, Sedimentation & Rheology

An ideal pharmaceutical suspension is flocculated: particles form loose, macroscopic aggregates (flocs) governed by secondary van der Waals attractive forces. Although flocculated suspensions settle relatively rapidly, they create a large, porous sediment volume ($F \approx 1$) that redisperses completely upon gentle shaking:

$\text{Sedimentation Volume Ratio } (F) = \frac{\text{Ultimate Volume of Sediment } (V_u)}{\text{Initial Total Volume of Suspension } (V_o)}$

Conversely, deflocculated suspensions settle slowly into a dense, tightly packed sediment where repulsive zeta potentials are overcome, forming an irreversible "cake" that cannot be resuspended even with vigorous shaking. Inadvertent administration of a caked suspension results in catastrophic under-dosing initially, followed by a lethal overdose when the dense sediment at the bottom of the bottle is drawn up.

Common Pediatric Formulations & Dosing Scenarios

• Spironolactone Oral Suspension (5 mg/mL or 25 mg/mL): Used for congestive heart failure and bronchopulmonary dysplasia (dosing: 1 to 3 mg/kg/day divided every 12 to 24 hours; maximum 100 mg/day). Compounded by crushing spironolactone tablets in a 1:1 mixture of Ora-Plus and Ora-Sweet (or Ora-Sweet SF). Multiple peer-reviewed studies confirm chemical stability for 60 days at controlled room temperature or refrigerated.
• Ursodiol Oral Suspension (50 mg/mL): Indicated for parenteral nutrition-associated cholestasis (PNAC) and biliary atresia (dosing: 10 to 30 mg/kg/day divided every 8 to 12 hours). Compounded in Ora-Plus:Ora-Sweet (1:1); stable for 60 days at CRT or refrigerated.
• Baclofen Oral Suspension (5 mg/mL): Used for pediatric cerebral palsy spasticity (starting at 0.3 to 0.75 mg/kg/day divided every 8 hours, titrating to 1 to 2 mg/kg/day; maximum 40 to 60 mg/day). Stable in Ora-Plus:Ora-Sweet (1:1) for 60 days at CRT or refrigerated.

---

Evaluating Peer-Reviewed Stability Studies

Clinical pharmacists must distinguish between valid, peer-reviewed stability studies (published in journals such as the American Journal of Health-System Pharmacy [AJHP] or International Journal of Pharmaceutical Compounding [IJPC]) and simple anecdotal recipes. To support extending a BUD beyond default USP <795> limits, a published study must meet three rigorous criteria:

Core Criteria for Validating Compounding Stability Literature:

1. Validated Stability-Indicating HPLC Assay:
   - Baseline chromatographic resolution of intact parent API from degradation peaks.
   - Forced degradation stress testing: acid (HCl), base (NaOH), thermal, photolytic, and oxidative (H2O2).

2. Physical Stability & Rheological Integrity:
   - Documented visual uniformity, color, odor, redispersibility (<10-15 inversions), and absence of caking.
   - Strict maintenance of pH within ±0.5 units of baseline throughout study duration.

3. Antimicrobial Preservative Effectiveness (USP <51>):
   - Inoculation challenge demonstrating specified log-reductions against:
     S. aureus, P. aeruginosa, E. coli, C. albicans, and A. brasiliensis.

Analytical Pitfalls in the Literature

• Spectrophotometric (UV-Vis) Flaws: Simple UV-Vis spectrophotometry measures total light absorbance at a fixed wavelength. Degradation products often retain the parent drug's chromophore, yielding falsely elevated "100% active drug" readings in decomposed samples. Non-chromatographic assays are invalid for BUD extension.
• Packaging & Sorption: Studies must evaluate the exact container-closure system used in clinical practice (e.g., amber polyethylene terephthalate [PET] vs high-density polyethylene [HDPE] bottles vs clear oral syringes). Lipophilic active drugs (e.g., diazepam, vitamin A) adsorb significantly to plastic walls, reducing delivered potency.

---

Identifying Non-Crushable Solid Dosage Forms

Crushing tablets or opening capsules to compound oral liquids or administer via enteral feeding tubes (nasogastric, gastrostomy, jejunostomy) carries severe clinical hazards when applied to modified-release or coated solid dosage forms.

---

Practice Pearls & BCPPS Exam Traps

• The Preserved Vehicle Trap: If you mix commercial tablets into Ora-Plus and Ora-Sweet (preserved aqueous vehicle, $a_w \ge 0.60$), the default BUD under USP <795> is 35 days, NOT 14 days. The 14-day limit applies strictly to non-preserved aqueous oral liquids stored in a refrigerator.
• The Omeprazole Acid Trap: Omeprazole degrades within minutes in gastric acid ($pH < 2.0$). Crushing enteric-coated omeprazole tablets and suspending them in standard Ora-Plus:Ora-Sweet ($pH \approx 4.2$) destroys the drug. Omeprazole must be compounded in an alkaline vehicle containing 8.4% sodium bicarbonate (or SyrSpend SF Alka) to maintain $pH > 8.0$, neutralizing stomach acid upon ingestion to permit duodenal absorption.
• The OROS Concerta Trap: A common clinical error is attempting to crush Concerta (OROS methylphenidate) for pediatric administration via G-tube. Concerta consists of an insoluble plastic shell, an osmotic push engine, and a laser-drilled delivery port. Crushing it destroys the mechanism and causes immediate release of methylphenidate, precipitating severe tachycardia, hypertension, and agitation; G-tube patients must be converted to immediate-release liquid methylphenidate dosed 2 to 3 times daily.
• The Shortest Expiration Rule: Never assign a default 35-day or 90-day BUD without inspecting the manufacturer lot expiration dates on all source ingredients. The assigned BUD cannot exceed the expiration date of any component.